You’ve likely encountered the name Akkermansia muciniphila in discussions surrounding longevity, metabolic health, or even as a potential adjunct to GLP-1 receptor agonist therapies. As interest in gut microbiome modulation for health management grows, so too does the desire for clear, actionable guidance on how to incorporate beneficial bacteria like A. muciniphila into your regimen. A primary concern for many is not just whether to take it, but precisely how much, when, and with what considerations for safety and efficacy.
Understanding the optimal dosage and administration of any probiotic requires a careful review of the current scientific evidence. This article, updated for 2026, aims to provide an evidence-based framework for adults aged 35-65 seeking to manage metabolic health, weight, or blood sugar, offering insights into A. muciniphila supplementation grounded in clinical research rather than anecdotal claims.
FTC Disclosure: This article may contain affiliate links to products. We may receive a commission for purchases made through these links, but this does not influence our editorial content. Our recommendations are based on scientific evidence and product quality.
Understanding Akkermansia muciniphila: Mechanism and Rationale for Supplementation
Akkermansia muciniphila is a Gram-negative bacterium naturally residing in the human gut, specifically known for its ability to degrade mucin, the primary component of the intestinal mucus layer. Mucin degradation is proposed to stimulate renewal of the mucus layer and support barrier integrity, but this comes mainly from mouse and cell work, and reviews note potential risks from excessive mucin degradation [12][13].
Lower abundance has been seen in some studies of obesity, type 2 diabetes and ulcerative colitis, but these are associations that may reflect reverse causation, and results in inflammatory bowel disease differ by study [5][8][9][10][11]. Research suggests A. muciniphila has been linked to better metabolic health in mouse and cell work through proposed mechanisms such as gut barrier function and the Amuc_1100 protein; in people, low abundance is only an association [5][6][7].
Current Clinical Dosage Recommendations for Akkermansia muciniphila
The majority of human clinical trials investigating the benefits of oral Akkermansia muciniphila supplementation have utilized a specific dosage range. These trials are few and small, and none has established an effective intake level [11][2].
Regulators set daily limits for pasteurised Akkermansia from 21 to 40 billion cells, depending on age and agency
Each limit is an upper safety level for a defined group, set by that agency.
Regulatory opinions on pasteurised A. muciniphila as a novel food. The EFSA adult limit excludes pregnant and lactating women. Source: EFSA 2021; EFSA 2025
Data table
| Item | Value |
|---|---|
| EFSA, adults | 34billion cells per day |
| EFSA, ages 12 to under 14 | 21billion cells per day |
| EFSA, ages 14 to under 18 | 30billion cells per day |
| UK FSA and FSS, from age 12 | 40billion cells per day |
Embed this chart
Free to reuse on your site. Copy the code below; please keep the credit link.
Research note: In 2024 the UK Food Standards Agency and Food Standards Scotland judged pasteurised A. muciniphila safe in supplements and medical foods for people from 12 years of age at up to 4 × 1010 cells/day [19].
Human trials of A. muciniphila have used considerably higher doses than the 1 to 5 billion CFU counts common on general probiotic labels. The landmark proof-of-concept trial published in Nature Medicine (Depommier et al., 2019) enrolled 40 overweight, insulin-resistant adults, 32 of whom completed, and gave a daily dose of 1 x 1010 (10 billion) live or pasteurized A. muciniphila cells for three months.[1] The largest trial published to date, a 142-participant multicentre study in adults with metabolic syndrome, used 30 billion pasteurized cells daily for four months.[2] The trials in the verified research used 10 billion cells daily (the 2019 pilot, as printed in the source) or 30 billion [1][2], so the lower counts printed on many labels have no direct trial support at all.
It is important to distinguish between live CFUs and pasteurized (non-viable) cells. While traditional probiotics rely on live bacteria, research has shown that pasteurized A. muciniphila improved insulin sensitivity in the one human pilot that tested both forms while the live arm did not, but mouse results are mixed (one study needed viable cells) and the mechanism is unproven [14][15]. Both pasteurized and live products are sold, and many of the pasteurized ones cite the Depommier trial as the basis for their dosage.
Comparison of Dosage Forms and Efficacy
| Dosage Form | Typical Daily Range (CFUs/Cells) | Key Efficacy Considerations | Current Research Status |
|---|---|---|---|
| Live A. muciniphila (Viable) | 1×1010 (10 billion) in the Depommier live arm; a live strain (AKK-WST01) was also used in a 58-participant type 2 diabetes trial. | In the Depommier trial the live arm did not produce the metabolic improvements seen with the pasteurized arm. Stability and survival through the GI tract remain challenges. | Tested in two randomized human trials; in the type 2 diabetes trial, benefits appeared only in participants who started with low gut Akkermansia.[3] |
| Pasteurized A. muciniphila (Non-viable) | 1×1010 (10 billion) in the Depommier trial; 30 billion in the largest trial to date. Often expressed as billions of cells. | Improved insulin sensitivity in a proof-of-concept trial; the largest trial to date missed its primary endpoint across its full study population. Better stability and shelf-life than live forms. | Three randomized human trials published to date; results are mixed and appear to depend on baseline gut Akkermansia levels.[2][4] |
| Postbiotics/Fermentates | Variable, dependent on specific active compounds. | Focus on specific beneficial metabolites or bacterial components; may not contain whole cells. | Emerging area; less direct evidence for whole A. muciniphila effects. |
Based on the available evidence, 1 x 1010 (10 billion) pasteurized A. muciniphila cells per day is the dose used in the one small pilot (40 enrolled) in which the pasteurized arm improved insulin sensitivity. No dose-response trial exists, and EFSA judged that pilot’s low dose and short duration of limited value for safety [1][14][11].[1] A product supplying fewer than 10 billion cells is below every dose any published human trial has tested. Going higher is not clearly better either: the 142-participant trial used 30 billion cells daily and did not meet its primary endpoint across its full study population, with improvements appearing mainly in participants who started with low gut Akkermansia.[2]
When to Take Akkermansia muciniphila: Timing and Administration
Unlike some probiotics that require specific timing relative to meals for optimal survival of live cultures, the timing for pasteurized A. muciniphila is less critical. Since the bacteria are not viable, concerns about stomach acid degradation are mitigated.
Most clinical trials have administered A. muciniphila once daily, typically with a meal or at a consistent time each day. Taking it with a meal may help integrate it into the digestive process, though this is primarily for user convenience and adherence.
Consistency is paramount. Regular daily intake ensures a steady exposure to the beneficial bacterial components, allowing for sustained modulation of gut health and metabolic pathways. Establishing a routine, such as taking it with breakfast or dinner, can aid in adherence.
Safety Profile and Potential Side Effects
Akkermansia muciniphila has a good safety record in the human trials published so far. It is a natural inhabitant of the human gut; the Depommier trial reported that daily supplementation was safe and well tolerated over three months,[1] and the 90-participant weight-maintenance trial reported no serious adverse events related to the treatment.[4] That is a reassuring record, but it rests on a few hundred participants studied for months rather than years.
EFSA judged pasteurized Akkermansia safe for adults at 3.4 x 1010 cells a day, excluding pregnant and lactating women, and in 2025 said safety in pregnancy and lactation has not been established. It also called the 2019 pilot of limited value for safety because of its few subjects, low dose and short duration [11][19].
In the 142-adult trial, 104 of 142 participants had at least one adverse event, balanced between the pasteurized arm (51) and placebo (53) and mostly mild or moderate; [2] none of these trials singled out a characteristic side-effect pattern for A. muciniphila. Minor gastrointestinal complaints such as bloating or gas are commonly reported when starting probiotic supplements generally, and often settle as the gut adjusts, but that is a general observation about probiotics rather than a finding from the A. muciniphila trials specifically.
It is crucial to note that current research primarily focuses on pasteurized A. muciniphila. While generally safe, individuals with compromised immune systems, short bowel syndrome, or other severe gastrointestinal conditions should consult their healthcare provider before initiating any new supplement, including A. muciniphila.
Long-Term Use and Synergistic Approaches
The long-term effects of continuous A. muciniphila supplementation are still under investigation. Published trials have run from 12 weeks to roughly eight months: three months in Depommier,[1] 12 weeks in the type 2 diabetes trial,[3] four months in the 142-participant metabolic syndrome trial,[2] and an eight-week weight-loss phase followed by 24 weeks of maintenance in the 90-participant weight-maintenance trial.[4] Nothing longer than that has been published, so claims about multi-year use are extrapolation rather than evidence.
For optimal benefits, A. muciniphila supplementation should be viewed as part of a comprehensive lifestyle strategy. This includes a balanced diet rich in fiber and prebiotics, regular physical activity, and adequate sleep. These lifestyle factors are associated with a more diverse gut microbiome, but no trial has shown they enhance the effects of [17][18] A. muciniphila.
Specific dietary fibers, such as fructans and galactooligosaccharides, serve as prebiotics that can nourish beneficial gut bacteria, including those that may indirectly support A. muciniphila. While A. muciniphila itself consumes mucin, a diverse gut environment created by prebiotic consumption can foster overall gut health.
What to Look For When Buying Akkermansia muciniphila Supplements
When searching for an Akkermansia muciniphila supplement, consider the following key attributes to ensure you are selecting a high-quality, evidence-aligned product:
Firstly, prioritize products that clearly state the dosage in billions of cells. The one human trial reporting significant metabolic benefit used 10 billion (1010) pasteurized cells per day, so treat that as the reference dose rather than the low single billions, which no successful trial has tested. If you want the form with the most human data behind it, look for terms like “pasteurized Akkermansia muciniphila” or “heat-inactivated Akkermansia muciniphila.” Live, refrigerated products are also sold, including some listed on this page, and their labels count viable cells rather than heat-killed ones.
Secondly, verify that the product is third-party tested for purity and potency. Independent verification ensures that the supplement contains the stated amount of A. muciniphila and is free from contaminants. Certifications from organizations like NSF International or USP are good indicators of quality control.
Lastly, consider the presence of additional ingredients. Some supplements may combine A. muciniphila with prebiotics or other beneficial strains. While these combinations may offer synergistic benefits, ensure the primary A. muciniphila dosage is adequate and that any additional ingredients are clearly listed and understood. You can find options by searching for Akkermansia muciniphila supplement, gut barrier probiotic, or metabolic probiotic on major retailers.
Conclusion
Akkermansia muciniphila has shown mixed results in people: one small pilot improved insulin sensitivity with a pasteurized preparation, a larger trial missed its primary endpoint, and gut barrier effects come mainly from mouse and cell work [14][2][5]. The current evidence, primarily from studies using pasteurized forms, points to 1 x 1010 (10 billion) cells per day as the best-supported dose, and to a body of evidence that is still small, mixed, and dependent on where your own gut Akkermansia levels start.
While the science continues to evolve, incorporating A. muciniphila into your daily routine, alongside a healthy lifestyle, has not been shown to improve metabolic outcomes in people beyond the early trial results above [14][2]. Always consult with a healthcare professional before starting any new supplement, especially if you have underlying health conditions or are taking other medications.
Frequently Asked Questions (FAQ)
What is the recommended daily dosage of Akkermansia muciniphila?
The dose used in the one pilot that improved insulin sensitivity is 10 billion (1×10 [1][14]10) pasteurized cells: the amount used in the Depommier 2019 proof-of-concept trial, which is the trial that showed improved insulin sensitivity. A larger 142-participant trial used 30 billion cells daily but did not meet its primary endpoint across its full study population. The verified research does not confirm any trial dose below 10 billion cells [1][2].
When is the best time to take Akkermansia muciniphila?
Timing matters less for a pasteurized product than for a live one, because there are no viable cells whose survival through the stomach depends on when you take them. Check which form you have bought: if the label tells you to refrigerate it, treat it as a live probiotic and follow the manufacturer’s timing instructions. For either form, taking it once daily and consistently, often with a meal, is a common and effective approach.
Is Akkermansia muciniphila safe to take long-term?
Human clinical trials have reported adverse events that were mostly mild or moderate and balanced between Akkermansia and placebo [2][11]. That record covers trials lasting from 12 weeks to roughly eight months in a few hundred participants in total; use beyond that has not been studied, so sustained multi-year use is extrapolation rather than an evidence-backed claim.
Can Akkermansia muciniphila help with weight loss or blood sugar management?
Partly, and with important caveats. In the Depommier 2019 trial, pasteurized A. muciniphila significantly improved insulin sensitivity, but its effects on body weight and fat mass did not reach statistical significance. A later 90-participant trial found less weight regain after a low-energy diet, and a 58-participant type 2 diabetes trial found no difference from placebo overall, with body-weight, fat mass and HbA1c reductions only in the subgroup who started with low gut Akkermansia levels [3]. It is not a weight-loss drug and should be used as part of a comprehensive healthy lifestyle.
What is the difference between live and pasteurized Akkermansia muciniphila?
Live A. muciniphila contains viable bacteria, while pasteurized (heat-inactivated) forms do not. The human trial that showed metabolic benefit used the pasteurized form, and it was the pasteurized arm that improved insulin sensitivity. The reason is unknown, and mouse studies disagree on whether live or pasteurized cells work better [14][15][16]. Both forms are sold commercially.
Should I take Akkermansia muciniphila if I am on a GLP-1 receptor agonist medication?
If you are taking GLP-1 receptor agonists or any other prescription medication, it is essential to consult your healthcare provider before introducing any new supplements, including A. muciniphila, to ensure there are no contraindications or interactions.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
References
- Depommier C et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature Medicine (2019). PMID 31263284
- Suenaert P et al. Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels. Gut Microbes (2026). PMID 42343233
- Zhang L et al. Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: Efficacy depends on its baseline levels in the gut. Cell Metabolism (2025). PMID 39879980
- Mount S et al. Pasteurized Akkermansia muciniphila MucT for weight loss maintenance in people with overweight and obesity: a controlled randomized trial. Nature Medicine (2026). PMID 42120725
- Kobyliak N et al. Akkermansia muciniphila as a novel powerful bacterial player in the treatment of metabolic disorders. Minerva endocrinology (2022). PMID 35103461
- Cani PD et al. Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms. Nature reviews. Gastroenterology & hepatology (2022). PMID 35641786
- Noora Ottman et al. Pili-like proteins of Akkermansia muciniphila modulate host immune responses and gut barrier function. PLoS ONE (2017). PMID 28249045
- Ching‐Tang Shih et al. Akkermansia muciniphila is Negatively Correlated with Hemoglobin A1c in Refractory Diabetes. Microorganisms (2020). PMID 32899513
- Cao X et al. Detection of tissue colonizing bacteria and their association with clinicopathological and molecular features of inflammatory bowel disease. Journal of translational medicine (2025). PMID 41094525
- Mireia López‐Siles et al. Alterations in the Abundance and Co-occurrence of Akkermansia muciniphila and Faecalibacterium prausnitzii in the Colonic Mucosa of Inflammatory Bowel Disease Subjects. Frontiers in Cellular and Infection Microbiology (2018). PMID 30245977
- European Food Safety Authority (NDA Panel) Safety of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283. European Food Safety Authority (NDA Panel) (2021). source
- Ye WY et al. Akkermansia muciniphila: a microbial guardian against oxidative stress-gut microbiota crosstalk and clinical prospects. Journal of translational medicine (2025). PMID 41137026
- Miura K et al. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World journal of gastroenterology (2014). PMID 24966608
- Liu Y et al. Pasteurized Akkermansia muciniphila as a candidate multi-effector pharmacological system in the gut-liver axis: evidence, unresolved causality, and translational priorities. Frontiers in pharmacology (2026). PMID 42846334
- Amandine Everard et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proceedings of the National Academy of Sciences (2013). PMID 23671105
- Fatemeh Ashrafian et al. Comparative effects of alive and pasteurized Akkermansia muciniphila on normal diet-fed mice. Scientific Reports (2021). PMID 34504116
- Sanne Verhoog et al. Dietary Factors and Modulation of Bacteria Strains of Akkermansia muciniphila and Faecalibacterium prausnitzii: A Systematic Review. Nutrients (2019). PMID 31336737
- Yu M et al. Effects of anti-aging diets and exercise on age-related musculoskeletal diseases via gut microbiota modulation. Annals of medicine (2026). PMID 42773801
- EFSA Panel on Nutrition et al. Safety of an extension of use of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283. EFSA journal. European Food Safety Authority (2025). PMID 41018002
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
